Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


The Dutch Medicines Evaluation Board has signed off AXIM Biotechnologies’ MedChew Rx clinical development programme, which will see them develop and trial a cannabis based chewing gum.

The...

It is difficult to identify patients at risk of disease reactivation. So in a recent study scientists at Cerrahpasa School of Medicine, Istanbul University in Turkey compared the demographic and...

Researchers from Monash University in Australia are set to conduct a large study into a drug that may one day help halt the progression of multiple sclerosis (MS).

The preclinical study,...

A study, published at ECTRIMS 2017, has revealed that serum vitamin D levels could be involved in the regulation of the replication/reactivation of Epstein-Barr virus (EBV) in multiple sclerosis (...

An international team of researchers led by Professor Savvas Savvides, VIB-UGent Center for Inflammation Research, has unravelled a crucial aspect of the molecular basis of autoimmune and...

The U.S Food and Drug Administration (FDA) has denied a request for healthy individuals to consume vitamin D to reduce the risk of developing multiple sclerosis (MS). 

The FDA reviewed 85...

The European Commission (EC) has granted a licence for the use of ocrelizumab, also known as Ocrevus, in people with primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple...

Back in July 2017, the Medical and Healthcare products Regulatory Agency (MHRA) highlighted restrictions on the use of daclizumab (Zinbryta) for relapsing remitting multiple sclerosis (RRMS)...

Scientists have conducted a study that looks at how traditional initial disease modifying treatment (DMT) choices, including dimethyl fumarate, fingolimod, or natalizumab compare with rituximab in...

The regeneration of intact myelin sheaths is a necessary prerequisite for patients to recover from multiple sclerosis (MS) relapses. Nevertheless, the body's ability to regenerate myelin decreases...

Pages

Live Chat Software by Click4Assistance UK